David Storms's questions to Alpha Cognition (ACOG) leadership • Q1 2025
Question
David Storms asked about the expected patient penetration in targeted Tier 1 long-term care facilities and whether the current sales force is sufficient to scale. He also sought to clarify how much of the Q1 revenue represented initial stocking versus underlying demand. Lastly, he inquired about potential impacts from recent U.S. policy developments on long-term pricing.
Answer
COO Lauren D'Angelo explained that a significant portion of Alzheimer's patients in nursing homes are candidates for ZUNVEYL, as about half are untreated after failing previous therapies. CEO Michael McFadden stated the current sales force provides 80% coverage and any increases would be minor. D'Angelo clarified that initial stocking was minimal and has already been depleted for the 5mg dose, indicating strong underlying demand. McFadden addressed policy concerns, stating the company does not anticipate significant impacts from tariffs or reference pricing proposals on its U.S. business in the near term.